PALANDRI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 957
AS - Asia 607
EU - Europa 546
SA - Sud America 78
AF - Africa 14
OC - Oceania 7
Totale 2.209
Nazione #
US - Stati Uniti d'America 947
RU - Federazione Russa 301
CN - Cina 194
SG - Singapore 185
HK - Hong Kong 80
BR - Brasile 71
KR - Corea 65
IE - Irlanda 49
SE - Svezia 47
IT - Italia 42
DE - Germania 36
VN - Vietnam 26
FI - Finlandia 20
IN - India 16
GB - Regno Unito 14
ID - Indonesia 10
CH - Svizzera 9
FR - Francia 8
JO - Giordania 8
AU - Australia 7
CI - Costa d'Avorio 7
TR - Turchia 6
BD - Bangladesh 5
UA - Ucraina 5
JP - Giappone 4
MX - Messico 4
AT - Austria 3
CA - Canada 3
EC - Ecuador 3
NL - Olanda 3
PL - Polonia 3
AR - Argentina 2
BJ - Benin 2
DO - Repubblica Dominicana 2
IQ - Iraq 2
RO - Romania 2
AL - Albania 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CO - Colombia 1
DK - Danimarca 1
DZ - Algeria 1
ES - Italia 1
GE - Georgia 1
HN - Honduras 1
KE - Kenya 1
KZ - Kazakistan 1
MA - Marocco 1
MM - Myanmar 1
OM - Oman 1
SA - Arabia Saudita 1
SC - Seychelles 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 2.209
Città #
Santa Clara 451
Singapore 140
Ashburn 107
Hefei 71
Hong Kong 67
Seoul 65
Chandler 63
Dublin 49
Beijing 39
Los Angeles 21
Altamura 18
Lawrence 18
Moscow 17
Fairfield 12
Munich 12
Buffalo 11
Princeton 11
Boston 10
Seattle 10
Shanghai 10
Bern 9
Jacksonville 9
Jakarta 9
Cambridge 8
Kent 8
Lappeenranta 8
Woodbridge 8
Abidjan 7
Boardman 7
Melbourne 7
Mumbai 7
San Diego 7
Washington 7
Wilmington 7
London 6
Medford 6
São Paulo 6
Belo Horizonte 5
Hanoi 5
Helsinki 5
Ho Chi Minh City 5
Houston 5
Paris 5
Andover 4
Dallas 4
Frankfurt am Main 4
Izmir 4
New York 4
Tokyo 4
Turku 4
Bengaluru 3
Bremen 3
Brugherio 3
Chennai 3
Falkenstein 3
Lauterbourg 3
The Dalles 3
Vienna 3
Warsaw 3
Biên Hòa 2
Brooklyn 2
Chicago 2
Cotonou 2
Curitiba 2
Düsseldorf 2
Guarulhos 2
Haiphong 2
Manchester 2
Milan 2
Norwalk 2
Osasco 2
Phoenix 2
Pistoia 2
Rome 2
Salvador 2
Secaucus 2
Shenzhen 2
Taubaté 2
Thái Bình 2
Tianjin 2
Uberlândia 2
Almaty 1
Amman 1
Ann Arbor 1
Anápolis 1
Aransas Pass 1
Araçatuba 1
Arnsberg 1
Açu 1
Baghdad 1
Baku 1
Basra 1
Batumi 1
Beuningen 1
Bismarck 1
Britânia 1
Bueno Brandão 1
Bình Tân 1
Bắc Giang 1
Calgary 1
Totale 1.476
Nome #
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 148
A modified adenine chemically coupled to the allergen molecule of Dermatophagoides pteronyssinus redirects allergen-specific Th2 cells 136
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 131
Total serum IgE levels influence the in vitro detection of ss-lactams-specific IgE antibodies 128
A modified adenine chemically coupled to allergen molecule(s) induce Interferon-gamma production and down regulate IL-4 and IL-5 in Th2 specific T cells 127
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 126
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 125
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 125
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis 121
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey 121
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study 118
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 115
Long-term follow-up of recovered MPN patients with COVID-19 115
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 114
Incidence of blast phase in myelofibrosis according to anemia severity 113
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT 103
Breakthrough infections in MPN-COVID vaccinated patients 102
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options 75
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial 71
null 15
Totale 2.229
Categoria #
all - tutte 6.924
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.924


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202127 0 0 0 0 0 5 0 10 2 5 2 3
2021/202254 3 1 3 1 0 0 0 15 1 0 9 21
2022/2023251 18 56 15 17 17 37 26 17 29 5 3 11
2023/2024160 5 11 21 16 15 27 5 37 1 10 3 9
2024/20251.002 16 67 51 118 345 188 19 36 21 20 56 65
2025/2026665 132 170 131 71 152 9 0 0 0 0 0 0
Totale 2.229